| Patients (n = 50) | Controls (n = 12) | P-Value | CD62L p-value | CD62L correlation coefficient |
Age at KT (years) | 10.36 ± 3.84 | -------- | -------- | 0.32 | −0.15 |
Age at assessment (years) | 12.94 ± 4.23 | 10.7 ± 4.51 | 0.132 | 0.34 | −0.14 |
Sex (M/F) | 35/15 (70%/30%) | 8/4 (66.7%/33.3%) | 0.123 | -------- | -------- |
Post transplantation FU duration (mo) | 30.94 ± 16.51 | -------- | -------- | 0.69 | 0.06 |
Dialysis duration (mo) | 21.70 ± 25.34 | -------- | -------- | 0.12 | −0.23 |
BMI (Kg/m2) | 22.63 ± 7.88 | 23.60 ± 8.44 | 0.859 | 0.36 | −0.22 |
SBP (mmHg) | 109.40 ± 10.50 | 95.54 ± 9.70 | 0.0001 | 0.95 | 0.01 |
DBP (mmHg) | 70.40 ± 8.91 | 61.55 ± 10.10 | 0.0001 | 0.29 | 0.152 |
Donor Age (years) | 37.18 ± 6.21 | -------- | -------- | 0.04 | −0.29* |
Number of mismatch/6 | 2.5 ± 0.77 | -------- | -------- | 0.033 | 0.305* |
Cold ischemia time (minutes) | 52.45 ± 12.30 | -------- | -------- | 0.11 | −0.24 |
PRD dose at 1 mo (mg/day) | 19.02 ± 5.44 | -------- | -------- | 0.43 | 0.12 |
PRD dose at 12 mo (mg/day) | 4.23 ± 1.55 | -------- | -------- | 0.12 | −0.23 |
Trough CsA level (ng/ml) | 110.83 ± 18.55 | -------- | -------- | 0.62 | 0.26 |
Trough tacrolimus (ng/ml) | 6.26 ± 1.16 | -------- | -------- | 0.93 | 0.02 |
Serum creatinin (mg/dl) | 1.53 ± 3.01 | -------- | -------- | 0.086 | −0.250 |
eGFR (ml/min/1.73m2) | 76.20 ± 22.10 | 96 ± 18.8 | 0.0203 | 0.988 | −.002 |
HB (gm/dl) | 10.84 ± 1.17 | 14.23 ± 1.50 | <0.0001 | 0.83 | −0.04 |
HCT | 32.14 ± 4.20 | 38.88 ± 3.62 | 0.0001 | 0.34 | −0.17 |
TLC [×103/mm−3] | 7.83 ± 2.61 | 3.57 ± 1.42 | <0.0001 | 0.68 | 0.07 |
G count [×103/mm−3] | 49.70 ± 17.15 | 42.42.12.32 | 0.0181 | 0.74 | 0.06 |
L count [×103/mm−3] | 37.07 ± 16.64 | 22.20 ± 15.21 | <0.0001 | 0.83 | −0.04 |
PLT [×103/mm−3] | 223.06 ± 78.41 | 269.45 ± 84.02 | 0.0057 | 0.36 | 0.162 |
CD 4% | 34.32 ± 9.58 | 34.78 ± 10.01 | 0.882 | 0.0001 | 0.615 |
CD62L% | 44.74 ± 17.45 | 33.36 ± 11.54 | 0.02 | ------- | -------- |